New Drug Combination for Early-Stage Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a new drug called tarlatamab to a standard immunotherapy (durvalumab) works better than durvalumab alone for small cell lung cancer that hasn't spread widely. You would be eligible if you've already completed chemotherapy and radiation therapy and your cancer hasn't gotten worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with limited-stage small cell lung cancer (SCLC) and completed 3–4 cycles of chemotherapy plus radiation therapy
- No surgery or had surgery before this diagnosis, and cancer hasn't progressed (no new or worsening tumors)
- Age 18 or older with good overall health (ECOG performance status 0–1)
- Can start study treatment within 42 days of finishing chemotherapy or radiation
- Normal organ and blood cell counts; healthy heart (ejection fraction ≥50%), lungs, and kidneys
- No prior immunotherapy (like checkpoint inhibitors), no DLL3 inhibitors, and no other active cancer treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (atigotatug and nivolumab) against the standard drug durvalumab for people with limited-stage small cell lung cancer who have completed chemotherapy and radiation without the cancer getting worse. The goal is to see if the new combination works better at keeping the cancer from coming back.
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.